- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic iron overload
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 876KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 48KB)
Deferasirox – November 2020
Deferasirox: Dispersible tablet 125 mg, Dispersible tablet 250 mg, Dispersible tablet 500 mg; Deferasirox Juno®
Last updated
5 March 2021